Protective effect of ambroxol on pulmonary function after cardiopulmonary bypass

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 6, 2008, Pages 518-523

  Ulas, Mahmut Mustafa ^a   Hizarci, Mustafa ^a   Kunt, Aysegul ^a   Ergun, Kumral ^b   Kocabeyoglu, Sabit Sinan ^a,b   Korkmaz, Kemal ^a   Lafci, Gokhan ^a   Gedik, Selcuk ^a   Cagli, Kerim ^a  

^a Cardiovasc Surg Dept at T   (Turkey)

^b TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Ambroxol; Cardiopulmonary bypass; Pulmonary function

Indexed keywords

AMBROXOL; OXYGEN; PHOSPHATIDYLCHOLINE; RESPIRATORY TRACT AGENT; SPHINGOMYELIN;

ADULT; ARTERIAL GAS; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LECITHIN SPHINGOMYELIN RATIO; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; MORBIDITY; PRIORITY JOURNAL; BLOOD; CHEMISTRY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; LUNG; LUNG DISEASE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PERIOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VITAL CAPACITY;

ADMINISTRATION, ORAL; ADULT; AMBROXOL; BRONCHOALVEOLAR LAVAGE FLUID; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LECITHINS; LUNG; LUNG DISEASES; MALE; MIDDLE AGED; OXYGEN; PERIOPERATIVE CARE; RESPIRATORY SYSTEM AGENTS; SPHINGOMYELINS; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 59449111012     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31819036c7     Document Type: Article

References (35)

1. Cox CM, Ascione R, Cohen AM, et al. Effect of cardiopulmonary bypass on pulmonary gas exchange: a prospective randomized study. Ann Thorac Surg. 200;69:140-145.
2. Schuller D, Morrow LE. Pulmonary complications after coronary revascularization. Curr Opin Cardiol. 2000;15:309-315.
3. Matthay MA, Wiener-Kronish JP. Respiratory management after cardiac surgery. Chest. 1989;95:424-434.
4. Wan S, Le Clerc JL, Vincent JL. Inflammatory response to cardiopulmonary bypass: mechanism involved and possible therapeutic strategies. Chest. 1997;112:676-692.
5. Brasil LA, Gomes WJ, Salomao R, et al. Inflammatory response after myocardial revascularization with or without cardiopulmonary bypass. Ann Thorac Surg. 1998;66:56-59.
6. Levy JH, Tanaka KA. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg. 2003;75:S715-S720.
7. Ege T, Arar C, Canbaz S, et al. The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. Thorac Cardiovasc Surg. 2004;52:10-15.
8. Püschmann S, Engelhorn R. Pharmakologische Untersuchungen des Bromhexin-Mataboliten Ambroxol. Arzneim Forsch/Drug Res. 1978;28: 889-898.
9. Felix K, Pairet M, Zimmermann R. The antioxidative activity of the mucoregulatory agents: ambroxol, bromhexine and N-acetyl-L-cysteine. A pulse radiolysis study. Life Sci. 1996;59:1141-1147.
10. Pfeifer S, Zissel G, Kienast K, et al. Reduction of cytokine release of blood and bronchoalveolar mononuclear cells by ambroxol. Eur J Med Res. 1997;2:129-132.
11. Nowak D, Pietras T, Antczak A, et al. Ambroxol inhibits endotoxin-induced lipid peroxidation in mice. Pol J Pharmacol. 1993;45:317-322.
12. Bianchi M, Mantovani A, Erroi A, et al. Ambroxol inhibits interleukin-1 and tumor necrosis factor production in human mononuclear cells. Agents Actions. 1990;31:275-279.
13. Gibbs BF, Schmutzler W, Vollrath IB, et al. Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells. Inflamm Res. 1999;48:86-93.
14. Pairet M, Engelmann P, Von-Nicolzi H, et al. Ambroxol improves the broncho-spasmolytic activity of clenbuterol in the guinea pig. J Pharm Pharmacol. 1997;49:184-186.
15. Ratliff NB, Young WG, Hackel DB, et al. Pulmonary injury secondary to extracorporeal circulation. An ultrastructural study. J Thorac Cardiovasc Surg. 1973;65:425-432.
16. Angdin M, Settergren G, Starkopf J, et al. Protective effect of antioxidants on pulmonary endothelial function after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:314-320.
17. Jauch R, Bozler G, Hammer R, et al. Ambroxol, studies of bio-transformation in man and determination in biological samples (author's transl). Arzneimittelforschung. 1978;28:904-911.
18. Knudson RJ, Slatin RC, Lebowitz MD, et al. The maximal expiratory flow volume curve. Am Rev Respir Dis. 1976;113:587-600.
19. Shenkman Z, Shir Y, Weiss YG, et al. The effects of cardiac surgery on early and late pulmonary functions. Acta Anaesthesiol Scand. 1997;41: 1193-1199.
20. Romanini BM, Sandri MG, Tosi M, et al. Ambroxol for prophylaxis and treatment of bronchopulmonary complications after chest surgery. Int J Clin Pharmacol Res. 1986;6:123-127.
21. Macnaughton PD, Braude S, Hunter DN. Changes in lung function and pulmonary capillary permeability after cardiopulmonary bypass. Crit Care Med. 1992;20:1289-1294.
22. Tennenberg SD, Clardy CW, Bailey WW, et al. Complement activation and lung permeability during cardiopulmonary bypass. Ann Thorac Surg. 1990;50:597-601.
23. Jhonson D, Thomson D, Hurst T, et al. Neutrophil-mediated acute lung injury after extracorporeal perfusion. J Thorac Cardiovasc Surg. 1994; 107:1193-1202.
24. Kappelmayer J, Bernabei A, Edmunds LH Jr, et al. Tissue factor is expressed on monocytes during simulated extracorporeal circulation. Circ Res. 1993;72:1075-1081.
25. Fujiwara T, Seo N, Murayama T, et al. Transient rise in serum cytokines during coronary artery bypass grafting surgery. Eur Cytokine Netw. 1997; 8:61-66.
26. Lahat N, Zlotnick AY, Shtiller R, et al. Serum levels of IL-1, IL-6 and tumor necrosis factor in patients undergoing coronary artery bypass grafts or cholecystectomy. Clin Exp Immunol. 1992;89:255-260.
27. Jorens PG, Van Damme J, De Backer W, et al. Interleukin-8 in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. Cytokine. 1992; 4:592-597.
28. Marcatili S, Guarino C, Giannattasio A, et al. Alterations of the endoalveolar surfactant after surgery with extracorporeal circulation. Respiration. 1990;57:233-238.
29. Haughton W. Changes in pulmonary compliance in patients undergoing cardiac surgery. Dis Chest. 1968;53:617-628.
30. Gluck L, Kulovich MV, Borer RC Jr, et al. Diagnosis of the respiratory distress syndrome by amniocentesis. Am J Obstet Gynecol. 1971;109: 440-445.
31. Singh NP, Vargas FS, Cukier A, et al. Arterial blood gases after coronary artery bypass surgery. Chest. 1992;102:1337-1341.
32. Vargas FS, Terra-Filho M, Hueb W, et al. Pulmonary function after coronary artery bypass surgery. Respir Med. 1997;91:629-633.
33. Korsten HH, Leusink JA, Spierdijk J, et al. Pulmonary shunting after cardiopulmonary by-pass. Eur Heart J. 1989;10(suppl H):17-21.
34. Hales CA, Kazemi H. Small airways function in myocardial infarction. N Engl J Med. 1974;290:761-765.
35. West JB. Control of ventilation. How gas exchange is regulated? In: West JB, ed. Respiratory Physiology - The Essentials. Baltimore, MD: Williams & Wilkins; 1990:115-129.